ITCI250117C97500
- 0.65
- 0.000.00%
Intra-Cellular Therapies Newsroom
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $89
Intra-Cellular Therapies Receives Buy Rating Amid Promising Sales Projections and Strategic Developments
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $90 to $102
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $79 to $135
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
Intra-Cellular Therapies Analyst Ratings
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medpace Holdings (MEDP), Biohaven Ltd. (BHVN) and Intra-Cellular Therapies (ITCI)
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Intra-Cellular Therapies Analyst Ratings
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman